A breakthrough therapy for advanced breast cancer also works well in the early stages, allegedly improving survival outcomes for patients.

According to the pharmaceutical company Lilly Oncology, a phase 3 clinical trial has now confirmed that the Abemaciclib pill, sold under the brand name Verzenio, can significantly reduce the risk of relapse in some types of early breast cancer, which had spread to the lymph node.

Results from the seven-year follow-up are not yet peer-reviewed; however, the company promises to share the data at an upcoming medical meeting and submit a paper for peer review .

"These data validate Verzenio as the standard of care for patients with node-positive, high-risk disease and increase the urgency to ensure all eligible patients are treated," says J

See Full Page